

Cover Story
Lomustine, a.k.a. CCNU, is an old cancer drug.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Clinical Roundup


NCI Trials


NCI Trials for November 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - In her own words: Rathmell reflects on her priorities and values—and encourages everyone to do the same
- Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health
- Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas - Ci4CC’s 23rd Cancer Center Summit to focus on accelerating oncology innovation through AI
- White House preliminary budget document provides no funds for highly impactful CDC cancer registries program